Medtronic PLC $MDT Shares Acquired by Lazard Freres Gestion S.A.S.

Lazard Freres Gestion S.A.S. grew its position in Medtronic PLC (NYSE:MDT) by 6.4% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 1,530,777 shares of the medical technology company’s stock after buying an additional 91,505 shares during the period. Medtronic accounts for approximately 2.8% of Lazard Freres Gestion S.A.S.’s investment portfolio, making the stock its 10th largest holding. Lazard Freres Gestion S.A.S.’s holdings in Medtronic were worth $145,791,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. 1248 Management LLC bought a new position in shares of Medtronic in the 1st quarter valued at about $26,000. Delos Wealth Advisors LLC bought a new position in Medtronic in the second quarter valued at approximately $27,000. Tripletail Wealth Management LLC acquired a new stake in Medtronic during the 3rd quarter worth $34,000. GFG Capital LLC bought a new stake in shares of Medtronic during the 2nd quarter valued at $36,000. Finally, True Wealth Design LLC increased its holdings in Medtronic by 49.8% in the second quarter. True Wealth Design LLC now owns 421 shares of the medical technology company’s stock valued at $37,000 after purchasing an additional 140 shares during the last quarter. 82.06% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

MDT has been the subject of several recent analyst reports. Citigroup upped their target price on shares of Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. Jefferies Financial Group reissued a “hold” rating and issued a $110.00 target price on shares of Medtronic in a research report on Wednesday, November 19th. Leerink Partners set a $120.00 price target on shares of Medtronic and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. UBS Group upped their price objective on Medtronic from $95.00 to $102.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 19th. Finally, Morgan Stanley raised their target price on shares of Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a research note on Wednesday, November 19th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $109.94.

Medtronic Stock Performance

NYSE MDT opened at $96.13 on Friday. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $123.24 billion, a P/E ratio of 25.91, a P/E/G ratio of 2.53 and a beta of 0.71. The firm has a 50-day moving average price of $97.60 and a two-hundred day moving average price of $93.96. Medtronic PLC has a 12-month low of $79.38 and a 12-month high of $106.33.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. The firm had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company’s revenue was up 6.6% on a year-over-year basis. During the same quarter last year, the company earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Investors of record on Friday, December 26th will be given a dividend of $0.71 per share. The ex-dividend date is Friday, December 26th. This represents a $2.84 annualized dividend and a dividend yield of 3.0%. Medtronic’s dividend payout ratio (DPR) is currently 76.55%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).